Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.5552W HIGH $23.51
Volume
931.31 K
Value Traded
19.57 M
Short % Float
13.33%
-1.28%Week
+19.7%1 Month
+16.69%3 Month
+122.17%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.98 B
EPS (TTM)
-0.90
P/E Ratio
-
Ent. Value
2.87 B
Total Shares
95.10 M
Float Shares
94.15 M
Insiders
1.00%
Institutions
105.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
FTRE Catalyst Timeline
Dated clinical, regulatory and corporate events for Fortrea Holdings Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How FTRE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 88%
Micro Cap(rank 578 of 657)
Percentile Rank
Fortrea Holdings Inc. Common Stock faces pipeline headwinds (23/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every FTRE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Russell Carrie ElizabethOfficer (Interim CAO) | Sell | -246 2,384 held | $16.85 | 09/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FTRE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EAGLE HEALTH INVESTMENTS LP | 3.4 % (54.5 %) | 20.55 M | 1.18 M | -9.66% ( -126.29 K) |
FTRE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FTRE ranks across every disease it competes in
Competitive Position is a premium feature
See how FTRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFTRE News
-FTRE
Oct 5, 2026▲ +5.5%on this news
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Fortrea has announced the release date for its third quarter 2026 financial results, scheduled for October 29, 2026. The company will host a conference call at 8:00 a.m. ET to discuss these results. Participants are encouraged to pre-register and join the call early to avoid delays. The event will also be available via a live webcast.
Read more →-FTRE
Sep 10, 2026Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea has announced the granting of inducement awards to five newly hired employees, including its new CFO, Jason Knoblauch. The awards consist of restricted stock units (RSUs) and performance share units (PSUs) that will vest over three years, contingent on performance goals and continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract skilled professionals to the company.
Read more →-FTRE
Sep 10, 2026Fortrea to Participate in September Investor Conferences
Fortrea (Nasdaq: FTRE) will participate in several investor conferences in September 2026, including the Baird 2026 Global Healthcare Conference and the Deutsche Bank 2026 Healthcare Summit. CEO Anshul Thakral and other executives will engage in discussions and meetings with investors. The events are aimed at enhancing investor relations and showcasing Fortrea's role in clinical development solutions.
Read more →-FTRE
Sep 3, 2026Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials
Fortrea has announced a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials. This acquisition includes a bioanalytical laboratory and a clinical pharmacology unit, enhancing Fortrea's ability to conduct early-phase clinical studies. The deal is valued at approximately $45 million and aims to streamline operations and improve clinical development processes.
Read more →-FTRE
Sep 3, 2026Fortrea Akan Mengakuisisi Unit Farmakologi Klinis dan Operasional Laboratorium Bionalitik dari Worldwide Clinical Trials
Fortrea has signed a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials, which includes a bioanalytical laboratory and a clinical pharmacology unit. This acquisition aims to enhance Fortrea's integrated clinical development solutions and support its growth strategy. The deal is valued at approximately $45 million and is expected to close after regulatory approvals.
Read more →-FTRE
Sep 3, 2026Fortrea Akan Mengambil Alih Unit Farmakologi Klinikal dan Operasi Makmal Bioanalisis daripada Worldwide Clinical Trials
Fortrea has signed a definitive agreement to acquire the Early Phase Services segment from Worldwide Clinical Trials. This acquisition includes a 60,000 square foot bioanalytical lab and a 200-bed clinical pharmacology unit. The move aims to enhance Fortrea's capabilities in early-phase clinical studies and strengthen its end-to-end clinical development platform.
Read more →-FTRE
Sep 2, 2026Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
Fortrea has signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials. This acquisition includes a bioanalytical lab and a clinical pharmacology unit, enhancing Fortrea's capabilities in early-phase clinical development. The deal, valued at approximately $45 million, is expected to close pending regulatory approvals and will improve service delivery for clinical studies.
Read more →-FTRE
Jul 29, 2026Fortrea Reports Second Quarter 2026 Results
Fortrea reported its second quarter 2026 financial results, showcasing revenues of $678.2 million and an adjusted net income of $22.7 million. The company has raised its full-year guidance, reflecting confidence in its operational strategy. Despite a GAAP net loss, Fortrea achieved a book-to-bill ratio of 1.06x, marking its fourth consecutive quarter above this threshold.
Read more →-FTRE
Jul 13, 2026Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
Fortrea has announced the release date for its second quarter 2026 financial results, which will occur before the market opens on July 29, 2026. A conference call will follow at 8:00 a.m. ET to discuss these results. Participants can pre-register for the call and access a live webcast on the company's investor website.
Read more →-FTRE
Jun 26, 2026Fortrea Names Jason Knoblauch as Chief Financial Officer
Fortrea has appointed Jason Knoblauch as its new Chief Financial Officer, effective July 6, 2026. He succeeds Jill McConnell, who played a pivotal role in the company's growth as a leading global contract research organization. Knoblauch's previous experience includes CFO roles at Clario and Curia, and he is expected to contribute significantly to Fortrea's strategic objectives.
Read more →-FTRE
Jun 2, 2026Fortrea to Attend Jefferies Global Healthcare Conference
Fortrea, a global contract research organization, announced its participation in the Jefferies Global Healthcare Conference on June 4, 2026. CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will represent the company. The event will feature a fireside chat format, allowing for investor interaction and engagement.
Read more →-FTRE
May 5, 2026▲ +18.6%on this news
Fortrea Reports First Quarter 2026 Results Strong first-quarter performance reinforces confidence in FY 2026 guidance
Fortrea reported its financial results for the first quarter of 2026, revealing a revenue of $636.5 million, a decrease from $651.3 million in the same quarter of 2025. Despite a net loss of $23.6 million, the company confirmed its full-year guidance and maintained a book-to-bill ratio of 1.15x for the quarter. The adjusted net income showed significant improvement, and the company expressed confidence in its strategic growth plans and operational effectiveness.
Read more →-FTRE
Apr 21, 2026Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
Fortrea has announced the release date for its first quarter 2026 financial results, scheduled for May 5, 2026. The company will host a conference call at 8:00 a.m. ET to discuss these results. Participants are encouraged to pre-register for the call to receive dial-in details. A live webcast will also be available for access.
Read more →-FTRE
Feb 26, 2026Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
Fortrea reported its financial results for Q4 and full year 2025, showing a revenue of $660.5 million for Q4 and $2,723.4 million for the full year. The company experienced a significant GAAP net loss due to a goodwill impairment charge. Despite challenges, Fortrea's adjusted net income improved, and it provided optimistic guidance for 2026, targeting revenues between $2,550 million and $2,650 million.
Read more →-FTRE
Feb 17, 2026Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
Fortrea has expanded its executive team by appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services. Cohen will focus on medical strategy and client relationships, while Dove brings over 25 years of drug development experience to enhance early clinical development solutions. This leadership change aims to strengthen Fortrea's offerings in clinical research.
Read more →-FTRE
Jan 29, 2026Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
Fortrea has announced the release date for its fourth quarter and full year 2025 financial results, scheduled for February 26, 2026. The company will host a conference call at 8:00 am ET to discuss these results and answer questions. Participants are encouraged to register in advance to ensure smooth access to the call.
Read more →-FTRE
Jan 27, 2026Fortrea Appoints William Sharbaugh to Board of Directors
Fortrea has appointed William Sharbaugh to its Board of Directors, bringing over three decades of experience in the pharmaceutical industry. Sharbaugh's background includes leadership roles in CRO and pharmaceutical operations, which Fortrea's CEO believes will enhance the company's ability to deliver high-quality drug development. He aims to provide valuable insights and create stakeholder value.
Read more →-FTRE
Jan 27, 2026Fortrea to Present at the Jefferies Global Healthcare Conference
Fortrea, a prominent global contract research organization, will present at the Jefferies Global Healthcare Conference on June 5, 2025. The presentation will be led by Chairman Peter M. Neupert and CFO Jill McConnell. Investors can access the live webcast on the company's Investor Relations website, with a replay available afterward.
Read more →About Fortrea Holdings Inc. Common Stock
Headquarters8 MOORE DRIVE, DURHAM, NC, 27709
BIOPHARMAWATCH ELITE PLUS
Trade the next FTRE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime